These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7592185)

  • 1. Treatment of experimental rabbit infective endocarditis due to a multidrug-resistant Pseudomonas aeruginosa with high-dose ceftazidime alone and combined with amikacin or sulbactam or both.
    Xiong YQ; Caillon J; Zhou XY; Potel G; Bugnon D; Le Conte P; Le Gallou F; Le Floch R; Baron D; Drugeon H
    J Antimicrob Chemother; 1995 May; 35(5):697-706. PubMed ID: 7592185
    [No Abstract]   [Full Text] [Related]  

  • 2. Amikacin + ceftazidime therapy of experimental right-sided Pseudomonas aeruginosa endocarditis in rabbits.
    Bayer AS; Lam K; Norman D; Kim KS; Morrison JO
    Chemotherapy; 1985; 31(5):351-61. PubMed ID: 3931992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.
    Bayer AS; Norman D; Kim KS
    Antimicrob Agents Chemother; 1985 Dec; 28(6):781-5. PubMed ID: 3909954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis.
    Pefanis A; Giamarellou H; Karayiannakos P; Donta I
    Antimicrob Agents Chemother; 1993 Feb; 37(2):308-13. PubMed ID: 8452362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis.
    Bayer AS; Hirano L; Yih J
    Antimicrob Agents Chemother; 1988 Feb; 32(2):231-5. PubMed ID: 3129985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan.
    Leung CH; Wang NY; Liu CP; Weng LC; Hsieh FC; Lee CM
    J Microbiol Immunol Infect; 2008 Dec; 41(6):491-8. PubMed ID: 19255693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dynamic analysis of drug resistance of Pseudomonas aeruginosa in laboratory and clinical two-drug regimen].
    Tian BW; Yang YJ; Pang XY
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Aug; 25(8):1009-11. PubMed ID: 16109563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amikacin and cefoperazone/sulbactam alone or in combination against carbapenem-resistant Pseudomonas aeruginosa.
    Cai Y; Yang D; Wang J; Wang R
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):186-190. PubMed ID: 29486972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime and amikacin alone and in combination against Pseudomonas aeruginosa and Enterobacteriaceae.
    Moody JA; Fasching CE; Peterson LR; Gerding DN
    Diagn Microbiol Infect Dis; 1987 Jan; 6(1):59-67. PubMed ID: 3100127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa.
    Piccoli L; Guerrini M; Felici A; Marchetti F
    J Chemother; 2005 Aug; 17(4):355-60. PubMed ID: 16167512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudomonas peritonitis in neutropenic rats treated with amikacin, ceftazidime and ticarcillin, alone and in combination.
    Shyu WC; Nightingale CH; Quintiliani R
    J Antimicrob Chemother; 1987 Jun; 19(6):807-14. PubMed ID: 3112102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
    Sader HS; Huband MD; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of ciprofloxacin in experimental aortic valve endocarditis caused by a multiply beta-lactam-resistant variant of Pseudomonas aeruginosa stably derepressed for beta-lactamase production.
    Bayer AS; Lindsay P; Yih J; Hirano L; Lee D; Blomquist IK
    Antimicrob Agents Chemother; 1986 Oct; 30(4):528-31. PubMed ID: 3539007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model.
    Xiong YQ; Caillon J; Kergueris MF; Drugeon H; Baron D; Potel G; Bayer AS
    Antimicrob Agents Chemother; 1997 Apr; 41(4):823-6. PubMed ID: 9087497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum bactericidal activity and killing rate for volunteers receiving imipenem, imipenem plus amikacin, and ceftazidime plus amikacin against Pseudomonas aeruginosa.
    Van der Auwera P; Klastersky J; Lagast H; Husson M
    Antimicrob Agents Chemother; 1986 Jul; 30(1):122-6. PubMed ID: 3092729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postantibiotic effect of a combination of antimicrobial agents on pseudomonas aeruginosa.
    Sood P; Mandal A; Mishra B
    Chemotherapy; 2000; 46(3):173-6. PubMed ID: 10765031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The impact of antibiotic use on hospital-acquired pneumonia: data of etiology tests].
    Vitkauskiene A; Sakalauskas R; Dudzevicius V
    Medicina (Kaunas); 2003; 39(3):254-9. PubMed ID: 12695638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro efficacy of various antibiotic combinations against Pseudomonas aeruginosa isolates.
    Nazli E; Zer Y; Eksi F
    J Int Med Res; 2015 Apr; 43(2):217-25. PubMed ID: 25547417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of n-6 polyunsaturated fatty acids on growth of multidrug-resistant Pseudomonas aeruginosa: interactions with amikacin and ceftazidime.
    Giamarellos-Bourboulis EJ; Grecka P; Dionyssiou-Asteriou A; Giamarellou H
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2187-9. PubMed ID: 10898699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.